BRD4/CK2-IN-1
目录号: PL13500 纯度: ≥98%
CAS No. :2756851-99-5
商品编号 规格 价格 会员价 是否有货 数量
PL13500-5mg 5mg ¥2781.82 请登录
PL13500-10mg 10mg ¥4228.36 请登录
PL13500-25mg 25mg ¥8345.45 请登录
PL13500-50mg 50mg ¥13352.73 请登录
PL13500-100mg 100mg 询价 询价
PL13500-200mg 200mg 询价 询价
PL13500-10mM*1mLinDMSO 10mM*1mLinDMSO ¥3060.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
BRD4/CK2-IN-1
中文别名
乙酰胺,N-[3-氯-4-(4-甲基-1-哌嗪基)苯基]-2-[4-(3,4-二氢-5,7-二甲氧基-4-氧代-2-喹唑啉基)苯氧基]-
英文名称
BRD4/CK2-IN-1
英文别名
Acetamide, N-[3-chloro-4-(4-methyl-1-piperazinyl)phenyl]-2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)phenoxy]-;BRD4/CK2-IN-1
Cas No.
2756851-99-5
分子式
C29H30ClN5O5
分子量
564.03
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
BRD4/CK2-IN-1 是一种首次高效、口服有效的 BRD4/CK2 (含溴结构域蛋白 4/酪蛋白激酶 2) 双靶点抑制剂。BRD4/CK2-IN-1 对 BRD4 和 CK2 的 IC50 值分别为 180 nM 和 230 nM。BRD4/CK2-IN-1具有很强的抗癌活性,且无明显毒性。BRD4/CK2-IN-1 在三阴性乳腺癌 (TNBC) 中诱导细胞凋亡和自噬相关的细胞死亡。
生物活性
BRD4/CK2-IN-1 is the first highly effective and oral active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), with IC 50 s of 180 nM and 230 nM for BRD4 and CK2, respectively. BRD4/CK2-IN-1 has strong anticancer activity without obvious toxicities. BRD4/CK2-IN-1 induces apoptosis and autophagy-associated cell death in triple-negative breast cancer (TNBC)
性状
Solid
IC50 & Target[1][2]
BRD4 180 nM (IC50) CK2 230 nM (IC50
体外研究(In Vitro)
BRD4/CK2-IN-1 (compound 44e) (0-25 μM; 24 hours) has anti-proliferation effect with IC50s of 2.66 and 3.52 μM in MDA-MB-231 and MDA-MB-468 cells, respectively.
BRD4/CK2-IN-1 (0-10 μM; 24 hours) dose-dependently induces apoptosis of MDA-MB-231 and MDA-MB-468 cells.
BRD4/CK2-IN-1 (0-10 μM; 24 hours) dose-dependently downregulates Bcl-2 but upregulates Bax and cleaved caspase-3.
BRD4/CK2-IN-1 (0-10 μM; 24 hours) significantly downregulates the autophagy substrate p62 and up-regulated beclin-1 and LC3II in MDA-MB-231 and MDA-MB. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
BRD4/CK2-IN-1 (25 and 50 mg/kg; intragastric administration; daily for 19 days) inhibits tumor growth in TNBC xenograft models.
BRD4/CK2-IN-1 (25 and 50mg/kg; intragastric administration; daily for 19 days) shows weak toxicity measured by body weight loss in the MDA-MB-231 and MDA-MB-468 xenograft models.
Preliminary Assessment of Pharmacokinetics (PK) profile of BRD4/CK2-IN-1.
Parameter iv (1 mg/kg)
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Zhang J, et al. Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy. J Med Chem. 2021;64(24):18025-18053.
溶解度数据
In Vitro: DMSO : 20 mg/mL (35.46 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 60°C)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2